Eledon Pharmaceuticals, Inc. Annual Report Guide - How They Did This Year

Hey there! Thinking about Eledon Pharmaceuticals? Let's break down what they've been up to this past year (which ended December 31, 2025) and what it might mean for you as an investor. We'll keep it simple, like we're just chatting about it.

Here's what we'll cover:

1. What does this company do and how did they perform this year?

   • Eledon Pharmaceuticals develops treatments for organ transplants, autoimmune diseases, and nerve-related disorders. They are a clinical-stage company, meaning their products are still in testing.
   • Their main drug, tegoprubart (AT-1501), is a new antibody. It aims to adjust how the immune system responds. This report covers their work through December 31, 2025.
   • Tegoprubart is in several clinical trials. These include a Phase 2 study for ALS and another for kidney transplant rejection. A Phase 1b/2a study also tests it for islet cell transplantation. The drug targets CD40L. This molecule helps activate immune cells. The goal is to prevent or treat immune diseases. It aims to do this without broadly suppressing the immune system.
   • You can find their stock on the Nasdaq Capital Market. Their ticker symbol is ELDN.
   • By June 30, 2025, regular investors owned about $145.2 million worth of their common stock. (This excludes company insiders). As of March 13, 2026, about 75.8 million shares of common stock existed. These figures offer a basic idea of the company's market size.
   • They are a "smaller reporting company" and a "non-accelerated filer." This means their reporting rules are simpler than for much larger companies.

2. Financial performance - revenue, profit, growth metrics (How much money did they make? Are they growing? Did they make a profit?)

   • For the year ending December 31, 2025, Eledon brought in $0.5 million in revenue. Most of this came from grants. This is down from $1.2 million in 2024. As a clinical-stage company, they don't yet sell products.
   • The company lost $75.8 million in 2025. This is more than their $68.5 million loss in 2024. This 10.7% bigger loss shows their large investment in drug development.
   • Research and development (R&D) costs drove most operating expenses. They totaled $60.2 million in 2025, up from $55.0 million in 2024. This 9.5% increase came mainly from ongoing Phase 2 trials for tegoprubart. These trials are for ALS and kidney transplants. Costs included more patient enrollment and manufacturing for clinical supplies.
   • General and administrative (G&A) costs also grew. They hit $18.1 million in 2025, up from $15.5 million in 2024. This 16.8% increase was mostly due to higher staff costs and professional fees.

3. Major wins and challenges this year (What big successes did they have? What tough spots did they hit?)

   • Major Wins:
     • Eledon finished enrolling patients for the Phase 2 LIGHTHOUSE study of tegoprubart for ALS in Q3 2025. This is a key step before they get the main study results.
     • The company shared positive early results from the Phase 2 OPTIMIZE study in Q4 2025. This study tests tegoprubart in kidney transplant patients. The data showed a good safety profile. It also suggested fewer acute rejections compared to current treatments.
     • In Q2 2025, Eledon sold more shares to the public. They raised about $45.0 million. This greatly boosted their cash to fund ongoing drug development.
   • Challenges:
     • They planned to start a new Phase 2 study for tegoprubart in Type 1 Diabetes. This was delayed from Q4 2025 to Q1 2026. The delay happened because of unexpected problems scaling up drug manufacturing.
     • Higher R&D and operating costs led to a bigger loss than expected. This put pressure on their money. It also required careful cash management.

4. Financial health - cash, debt, liquidity (Do they have enough cash? Are they in debt? Can they easily pay their bills?)

   • By December 31, 2025, Eledon had $95.3 million in cash. This is down from $130.5 million at the end of 2024. They used a lot of cash for operations. Money from selling new shares helped offset some of this.
   • Their working capital (money to cover short-term needs) was $88.7 million at year-end 2025.
   • Eledon has a strong financial standing. They had no major long-term debt by December 31, 2025. They mainly fund operations by selling stock.
   • They spent about $18.0 million each quarter in 2025 (their "cash burn rate"). Based on their plans, their current cash should fund operations into Q3 2027. This includes the money raised from selling shares in Q2 2025.

5. Key risks that could hurt the stock price (What are the big things that could go wrong and affect your investment?)

   • Clinical Trial Outcomes: The biggest risk is that clinical trial results are uncertain. Tegoprubart might not meet its main goals in current or future trials. This includes the Phase 2 ALS LIGHTHOUSE study results due in Q2 2026. Bad or unclear data could significantly drop the company's value and stock price.
   • Regulatory Approval: Even with good clinical data, tegoprubart might not get approval. The FDA or other international agencies could deny it. Approving new immune-modifying drugs is complex and takes time. Rules can also change.
   • Need for Additional Financing: Eledon has no products for sale yet. They heavily rely on raising more money. This funds their expensive late-stage trials and future sales efforts. If they can't get enough funding on good terms, they might delay, shrink, or even stop their drug programs.
   • Competition: Eledon targets highly competitive areas. These include ALS and organ transplantation. Other drug companies already have or are developing treatments. These could limit tegoprubart's market potential, even if approved.
   • Intellectual Property Protection: Eledon's success depends on protecting its patents. This includes tegoprubart and other drugs in development. Challenges to their patents could reduce their market exclusivity. This would greatly impact future profits.

6. Competitive positioning (How do they stack up against other companies in their field?)

   • In the ALS market, Eledon competes with approved drugs. These include Relyvrio (Amylyx Pharmaceuticals) and tofersen (Biogen). Many other drugs in testing also target different disease pathways. Tegoprubart aims to stand out by targeting CD40L. This new method adjusts nerve inflammation and immune cell activity. It could offer a unique way to slow ALS progression compared to current treatments.
   • For organ transplantation, especially kidney rejection, Eledon competes with existing drugs. These include tacrolimus, mycophenolate mofetil, and sirolimus. Other drugs in testing also compete. Tegoprubart's anti-CD40L approach aims for more targeted immune suppression. This could reduce broad side effects from current treatments. It might also improve long-term organ survival.

7. Leadership or strategy changes (Any new bosses or big shifts in how they plan to run the company?)

   • In Q3 2025, Dr. David Clark became the new Chief Medical Officer (CMO). He brings over 20 years of experience. This includes immunology and clinical development at major drug companies. His hiring should greatly improve clinical trial design, execution, and regulatory plans for tegoprubart.
   • The company confirmed its main strategy. They will keep advancing tegoprubart for its three key uses: ALS, kidney transplant, and islet cell transplant. To use resources better and extend their cash, Eledon made a strategic choice. They will focus less on earlier-stage lab programs. Instead, they will concentrate efforts and money on their most promising clinical drugs.

8. Future outlook (What are their plans and hopes for the coming year?)

   • Eledon Pharmaceuticals expects several key milestones in 2026. These are vital for their future direction.
   • In Q2 2026, the company plans to announce main results from its key Phase 2 LIGHTHOUSE study for ALS. This will be a big event for the stock.
   • If Phase 2 data is good and they get more funding, Eledon plans to start a Phase 3 trial for tegoprubart. This trial, for kidney transplant rejection, would begin in the second half of 2026.
   • After solving manufacturing issues, the company expects to start a Phase 2 study for tegoprubart in Type 1 Diabetes in Q3 2026.
   • Eledon keeps looking for strategic partners. These partnerships would help develop and potentially sell tegoprubart. This is especially true for uses needing bigger trials or wider market access.

9. Market trends or regulatory changes affecting them (Are there bigger industry changes or new rules that could impact them?)

   • Eledon still benefits from Orphan Drug Designation for tegoprubart in ALS. This gives them big perks. These include tax credits for research and FDA fee exemptions. It also offers potential market exclusivity for seven years after U.S. approval.
   • The FDA increasingly uses accelerated approval pathways. This is for serious conditions lacking good treatments. It's especially true for nerve-related diseases like ALS. This could speed up tegoprubart's market entry. This depends on strong clinical data from its trials.
   • The wider drug market better understands the immune system's role. This applies to many diseases, including nerve and autoimmune disorders. This trend helps develop new immune-adjusting treatments like tegoprubart. However, it also increases competition in drug research.
   • Eledon isn't selling products yet, so this doesn't affect them immediately. But political and public focus on drug pricing continues. This is especially true for new, expensive treatments. It could impact future sales and market access once tegoprubart is ready to sell.

Considering these points, you now have a clearer picture of Eledon Pharmaceuticals' current standing and future potential as you weigh your investment decisions.